Erlotinib as adjuvant therapy in EGFR-mutant NSCLC
- 24 August 2018
- journal article
- editorial
- Published by Elsevier BV in The Lancet Respiratory Medicine
- Vol. 6 (11), 808-810
- https://doi.org/10.1016/s2213-2600(18)30307-2
Abstract
No abstract availableKeywords
This publication has 10 references indexed in Scilit:
- Erlotinib versus vinorelbine plus cisplatin as adjuvant therapy in Chinese patients with stage IIIA EGFR mutation-positive non-small-cell lung cancer (EVAN) a randomised, open-label, phase 2 trialThe Lancet Respiratory Medicine, 2018
- Gefitinib versus vinorelbine plus cisplatin as adjuvant treatment for stage II-IIIA (N1-N2) EGFR-mutant NSCLC (ADJUVANT/CTONG1104): a randomised, open-label, phase 3 studyThe Lancet Oncology, 2018
- Adjuvant Erlotinib Versus Placebo in Patients With Stage IB-IIIA Non–Small-Cell Lung Cancer (RADIANT): A Randomized, Double-Blind, Phase III TrialJournal of Clinical Oncology, 2015
- Gefitinib Versus Placebo in Completely Resected Non–Small-Cell Lung Cancer: Results of the NCIC CTG BR19 StudyJournal of Clinical Oncology, 2013
- Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trialThe Lancet, 2009
- Trastuzumab plus Adjuvant Chemotherapy for Operable HER2-Positive Breast CancerThe New England Journal of Medicine, 2005
- Trastuzumab after Adjuvant Chemotherapy in HER2-Positive Breast CancerThe New England Journal of Medicine, 2005
- Efficacy of Gefitinib, an Inhibitor of the Epidermal Growth Factor Receptor Tyrosine Kinase, in Symptomatic Patients With Non–Small Cell Lung CancerJama-Journal Of The American Medical Association, 2003
- Multi-Institutional Randomized Phase II Trial of Gefitinib for Previously Treated Patients With Advanced Non–Small-Cell Lung CancerJournal of Clinical Oncology, 2003
- Use of Chemotherapy plus a Monoclonal Antibody against HER2 for Metastatic Breast Cancer That Overexpresses HER2The New England Journal of Medicine, 2001